SPKM001, a promising anti-SARS-CoV-2 monoclonal antibody, is being developed by the Institut Pasteur and SpikImm


Following encouraging initial results, which will be published shortly, the Institut Pasteur and SpikImm announce the development of the antibody SPKM001.

Paris, September 9, 2021

SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the Spike protein of the original SARS-CoV-2 strain and its variants.

Initial preclinical results tend to show that this new therapeutic tool is effective in vitro and in vivo. Clinical trials should be conducted to evaluate its efficacy in humans.

“Following those very promising results, we will continue SPKM001’s fast-track development and expect to start clinical trials in 2022 in Europe, North America or Brazil. SpikImm will also consider opportunities of strategic partnerships that could accelerate SPKM001 development and help patients access this novel therapy faster.” said Philippe Pouletty, MD, chairman of SpikImm and CEO of Truffle Capital.

The Institut Pasteur has recently signed an exclusive worldwide license agreement with SpikImm, a Paris-Based biotechnology company founded in 2021 by Truffle Capital and the Institut Pasteur, for the development of anti-SARS-CoV-2 (Covid-19) monoclonal antibodies (mAbs), including SPKM001.

More informations about Truflle Capital : www.truffle.com

Back to top